Lucid Diagnostics Inc. (LUCD) proudly announced a promising outcome from its initial prospective clinical validation study for its EsoGuard Esophageal DNA test. This innovative test is designed to detect esophageal precancers in their early stages.
According to the results of the study, EsoGuard demonstrated noteworthy sensitivity and negative predictive value. It was the first time a molecular diagnostic test showed such outstanding performance in identifying a precancerous condition.
Chief Medical Officer of Lucid, Victoria Lee, expressed her enthusiasm for these results stating, "These clinical validity and utility data, along with the endorsement from multiple national society guidelines and consensus statements, provide substantial evidence in favor of the EsoGuard esophageal precancer detection method. The gathered evidence contributes significantly to our goal of securing broad EsoGuard medical policy coverage and a clear path to Medicare and Medicaid Services (CMS) coverage."
Despite the positive news, Lucid's stock is currently experiencing a decline of 6.3 percent on the Nasdaq, dropping to $1.04.
